Comment
doi: 10.1038/nrendo.2010.56.
Obesity: Taranabant no longer developed as an antiobesity agent
- PMID: 20518102
- DOI: 10.1038/nrendo.2010.56
Item in Clipboard
Comment
Obesity: Taranabant no longer developed as an antiobesity agent
Nat Rev Endocrinol.
2010 Jun.
No abstract available
Comment on
-
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.Int J Obes (Lond). 2010 May;34(5):919-35. doi: 10.1038/ijo.2010.21. Epub 2010 Feb 16. Int J Obes (Lond). 2010. PMID: 20157323 Clinical Trial.
Similar articles
-
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.Int J Obes (Lond). 2010 May;34(5):919-35. doi: 10.1038/ijo.2010.21. Epub 2010 Feb 16. Int J Obes (Lond). 2010. PMID: 20157323 Clinical Trial.
-
Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?Cell Metab. 2008 Jan;7(1):1-2. doi: 10.1016/j.cmet.2007.12.006. Cell Metab. 2008. PMID: 18177717
-
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.J Clin Pharmacol. 2008 Apr;48(4):418-27. doi: 10.1177/0091270008314467. Epub 2008 Feb 7. J Clin Pharmacol. 2008. PMID: 18258750 Clinical Trial.
-
Taranabant, a novel cannabinoid type 1 receptor inverse agonist.Curr Opin Investig Drugs. 2008 Oct;9(10):1116-29. Curr Opin Investig Drugs. 2008. PMID: 18821475 Review.
-
Lack of correlation between antiobesity policy and obesity growth rates: review and analysis.Endocr Pract. 2012 Sep-Oct;18(5):737-44. doi: 10.4158/EP11379.RA. Endocr Pract. 2012. PMID: 22548947 Review.
Cited by
-
Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.Pharmacol Biochem Behav. 2020 Dec;199:173059. doi: 10.1016/j.pbb.2020.173059. Epub 2020 Oct 18. Pharmacol Biochem Behav. 2020. PMID: 33086126 Free PMC article. Review.
-
Pharmacotherapy for childhood obesity: present and future prospects.Int J Obes (Lond). 2013 Jan;37(1):1-15. doi: 10.1038/ijo.2012.144. Epub 2012 Aug 28. Int J Obes (Lond). 2013. PMID: 22929210 Free PMC article. Review.
-
Pharmacotherapies for obesity: past, current, and future therapies.J Obes. 2011;2011:179674. doi: 10.1155/2011/179674. Epub 2010 Dec 12. J Obes. 2011. PMID: 21197148 Free PMC article.
-
A head-to-head comparison of MM/PBSA and MM/GBSA in predicting binding affinities for the CB1 cannabinoid ligands.J Mol Model. 2024 Oct 31;30(11):390. doi: 10.1007/s00894-024-06189-4. J Mol Model. 2024. PMID: 39480515
-
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.Nat Rev Drug Discov. 2012 Sep;11(9):675-91. doi: 10.1038/nrd3739. Epub 2012 Aug 3. Nat Rev Drug Discov. 2012. PMID: 22858652 Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
